A major Indian pharmaceutical company announced disappointing financial results on Wednesday, with earnings falling well below expectations due to challenging conditions in the United States market and rising operational costs.
Cipla, which ranks as India’s third-largest drug manufacturer by sales volume, saw its consolidated net earnings plummet 54.6% compared to the same period last year, reaching 5.55 billion rupees (equivalent to $58 million) for the quarter that concluded on March 31. This performance fell significantly short of the 7.05 billion rupee average projection from financial analysts, based on data from LSEG.
The company’s overall operational revenue decreased by 2.8% to 65.41 billion rupees, which was below the anticipated 67.49 billion rupees that market experts had forecast. This shortfall was primarily attributed to declining sales performance in the crucial North American marketplace.
While the company’s domestic Indian market showed robust growth with revenue climbing 15% to reach 30.07 billion rupees, this positive performance was overshadowed by a substantial 26% drop in North American revenue, which fell to 14.14 billion rupees.
These two primary markets represent approximately three-quarters of the pharmaceutical company’s total sales volume.
Operating costs increased by nearly 8.5% to 18.82 billion rupees, driven by various expense increases throughout the organization.
Additionally, the company recorded an impairment charge of approximately 420.2 million rupees related to its associate investments, further contributing to financial pressure.
Financial analysts from Jefferies had previously indicated in their pre-earnings analysis that they anticipated continued decline in U.S. sales in the coming months due to deterioration in key product lines, with profit margins expected to remain constrained until new product launches gain momentum.
The company announced it will distribute a dividend payment of 13 rupees per share to shareholders.
A competing pharmaceutical company, Dr Reddy’s, also reported a significant quarterly profit decline on Tuesday, impacted by impairment charges related to its discontinued cancer treatment development program.
Despite the disappointing earnings report, Cipla’s stock price rose 4.23% during afternoon trading. However, the company’s shares have declined approximately 14.3% since the beginning of this year.
